معرفی
Inga Fröding is a Researcher at Karolinska Institutet's Department of Laboratory Medicine in Stockholm, Sweden, actively contributing to the Division of Clinical Microbiology and the Antimicrobial Resistance research group led by Professor Christian Giske. Her work focuses on combating antimicrobial resistance through genomic epidemiology and diagnostic innovation.
Her educational background includes a Doctor of Philosophy (PhD) from Karolinska Institutet's Department of Laboratory Medicine, awarded in 2019. Her doctoral thesis examined Bloodstream infections with ESBL-producing Enterobacterales: prediction, rapid diagnosis and molecular epidemiology.
Fröding's research centers on antimicrobial resistance mechanisms, particularly in Gram-negative pathogens like Enterobacterales and Staphylococcus species. She investigates transmission dynamics of high-risk clones including MRSA USA300 and carbapenemase-producing Klebsiella pneumoniae, with emphasis on bloodstream infections and rapid diagnostic methods. Her work bridges genomic analysis with clinical applications, developing EUCAST-based rapid susceptibility testing protocols that reduce incubation times from 24 to 4-6 hours.
Analysis of her 14 most recent publications (2012-2024) reveals consistent focus on genomic surveillance of antimicrobial-resistant pathogens across Europe. Key trends include tracking international spread of resistance genes (e.g., NDM-1, carbapenemases), optimizing rapid diagnostics for bloodstream infections, and characterizing transmission clusters of vancomycin-resistant Enterococcus and MRSA. Her collaborative work spans 15+ countries, demonstrating strong emphasis on One Health approaches to resistance monitoring.
As part of the Christian Giske research group, Fröding contributes to Karolinska Institutet's clinical microbiology laboratory operations at Huddinge campus, where her team investigates resistance mechanisms in pathogens causing hospital- and community-onset infections. Her work directly informs Swedish and European public health responses to emerging resistance threats.
